Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 Mar;139(3):715–723. doi: 10.1016/j.jaci.2017.01.004

Figure 3.

Figure 3

A) Phospho-STAT1 expression in CD4+ T cells stimulated with IFN-β (20 ng/mL) and IFN-γ (20 ng/mL) in a patient with STAT1 GOF mutation and in a healthy control. B) Phospho-STAT1 expression upon IFN-β (20ng/mL) stimulation in CD4+ T cells from control and STAT1 (E545K) patient pretreated for 4 hours with 10nM and 100nM concentrations of ruxolitinib (red line histogram) and tofacitinib (blue line histogram) or vehicle (DMSO, black lie histogram). Gray solid histogram corresponds to unstimulated cells (from ref. 43).